Leigh Perreault1, Sean A Newsom2, Allison Strauss1, Anna Kerege1, Darcy E Kahn1, Kathleen A Harrison1, Janet K Snell-Bergeon3, Travis Nemkov4, Angelo D'Alessandro4, Matthew R Jackman1, Paul S MacLean1, Bryan C Bergman1. 1. Endocrinology, Diabetes, and Metabolism, School of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA. 2. School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon, USA. 3. Barbara Davis Center for Childhood Diabetes, School of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA. 4. Department of Biochemistry and Molecular Genetics, School of Medicine, University of Colorado Anschutz Medical Campus, Denver, Colorado, USA.
Abstract
BACKGROUND: Accumulation of diacylglycerol (DAG) and sphingolipids is thought to promote skeletal muscle insulin resistance by altering cellular signaling specific to their location. However,the subcellular localization of bioactive lipids in human skeletal muscle is largely unknown. METHODS: We evaluated subcellular localization of skeletal muscle DAGs and sphingolipids in lean individuals (n = 15), endurance-trained athletes (n = 16), and obese men and women with (n = 12) and without type 2 diabetes (n = 15). Muscle biopsies were fractionated into sarcolemmal, cytosolic, mitochondrial/ER, and nuclear compartments. Lipids were measured using liquid chromatography tandem mass spectrometry, and insulin sensitivity was measured using hyperinsulinemic-euglycemic clamp. RESULTS: Sarcolemmal 1,2-DAGs were not significantly related to insulin sensitivity. Sarcolemmal ceramides were inversely related to insulin sensitivity, with a significant relationship found for the C18:0 species. Sarcolemmal sphingomyelins were also inversely related to insulin sensitivity, with the strongest relationships found for the C18:1, C18:0, and C18:2 species. In the mitochondrial/ER and nuclear fractions, 1,2-DAGs were positively related to, while ceramides were inversely related to, insulin sensitivity. Cytosolic lipids as well as 1,3-DAG, dihydroceramides, and glucosylceramides in any compartment were not related to insulin sensitivity. All sphingolipids but only specific DAGs administered to isolated mitochondria decreased mitochondrial state 3 respiration. CONCLUSION: These data reveal previously unknown differences in subcellular localization of skeletal muscle DAGs and sphingolipids that relate to whole-body insulin sensitivity and mitochondrial function in humans. These data suggest that whole-cell concentrations of lipids obscure meaningful differences in compartmentalization and suggest that subcellular localization of lipids should be considered when developing therapeutic interventions to treat insulin resistance. FUNDING: National Institutes of Health General Clinical Research Center (RR-00036), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK089170), NIDDK (T32 DK07658), and Colorado Nutrition Obesity Research Center (P30DK048520).
BACKGROUND: Accumulation of diacylglycerol (DAG) and sphingolipids is thought to promote skeletal muscle insulin resistance by altering cellular signaling specific to their location. However,the subcellular localization of bioactive lipids in human skeletal muscle is largely unknown. METHODS: We evaluated subcellular localization of skeletal muscle DAGs and sphingolipids in lean individuals (n = 15), endurance-trained athletes (n = 16), and obesemen and women with (n = 12) and without type 2 diabetes (n = 15). Muscle biopsies were fractionated into sarcolemmal, cytosolic, mitochondrial/ER, and nuclear compartments. Lipids were measured using liquid chromatography tandem mass spectrometry, and insulin sensitivity was measured using hyperinsulinemic-euglycemic clamp. RESULTS: Sarcolemmal 1,2-DAGs were not significantly related to insulin sensitivity. Sarcolemmal ceramides were inversely related to insulin sensitivity, with a significant relationship found for the C18:0 species. Sarcolemmal sphingomyelins were also inversely related to insulin sensitivity, with the strongest relationships found for the C18:1, C18:0, and C18:2 species. In the mitochondrial/ER and nuclear fractions, 1,2-DAGs were positively related to, while ceramides were inversely related to, insulin sensitivity. Cytosolic lipids as well as 1,3-DAG, dihydroceramides, and glucosylceramides in any compartment were not related to insulin sensitivity. All sphingolipids but only specific DAGs administered to isolated mitochondria decreased mitochondrial state 3 respiration. CONCLUSION: These data reveal previously unknown differences in subcellular localization of skeletal muscle DAGs and sphingolipids that relate to whole-body insulin sensitivity and mitochondrial function in humans. These data suggest that whole-cell concentrations of lipids obscure meaningful differences in compartmentalization and suggest that subcellular localization of lipids should be considered when developing therapeutic interventions to treat insulin resistance. FUNDING: National Institutes of Health General Clinical Research Center (RR-00036), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK089170), NIDDK (T32 DK07658), and Colorado Nutrition Obesity Research Center (P30DK048520).
Authors: Min Park; Vincent Kaddai; Jianhong Ching; Kevin T Fridianto; Ryan J Sieli; Shigeki Sugii; Scott A Summers Journal: J Biol Chem Date: 2016-10-04 Impact factor: 5.157
Authors: Sarah M Turpin; Hayley T Nicholls; Diana M Willmes; Arnaud Mourier; Susanne Brodesser; Claudia M Wunderlich; Jan Mauer; Elaine Xu; Philipp Hammerschmidt; Hella S Brönneke; Aleksandra Trifunovic; Giuseppe LoSasso; F Thomas Wunderlich; Jan-Wilhelm Kornfeld; Matthias Blüher; Martin Krönke; Jens C Brüning Journal: Cell Metab Date: 2014-10-07 Impact factor: 27.287
Authors: Andrew J Hoy; Amanda E Brandon; Nigel Turner; Matthew J Watt; Clinton R Bruce; Gregory J Cooney; Edward W Kraegen Journal: Am J Physiol Endocrinol Metab Date: 2009-04-14 Impact factor: 4.310
Authors: Julia Szendroedi; Toru Yoshimura; Esther Phielix; Chrysi Koliaki; Mellissa Marcucci; Dongyan Zhang; Tomas Jelenik; Janette Müller; Christian Herder; Peter Nowotny; Gerald I Shulman; Michael Roden Journal: Proc Natl Acad Sci U S A Date: 2014-06-16 Impact factor: 11.205
Authors: Stephan Sachs; Simona Zarini; Darcy E Kahn; Kathleen A Harrison; Leigh Perreault; Tzu Phang; Sean A Newsom; Allison Strauss; Anna Kerege; Jonathan A Schoen; Daniel H Bessesen; Thomas Schwarzmayr; Elisabeth Graf; Dominik Lutter; Jan Krumsiek; Susanna M Hofmann; Bryan C Bergman Journal: Am J Physiol Endocrinol Metab Date: 2019-01-08 Impact factor: 4.310
Authors: David J Orlicky; Andrew E Libby; Elise S Bales; Rachel H McMahan; Jenifer Monks; Francisco G La Rosa; James L McManaman Journal: J Physiol Date: 2019-01-02 Impact factor: 5.182
Authors: Benjamin J Ryan; Michael W Schleh; Cheehoon Ahn; Alison C Ludzki; Jenna B Gillen; Pallavi Varshney; Douglas W Van Pelt; Lisa M Pitchford; Thomas L Chenevert; Rachel A Gioscia-Ryan; Suzette M Howton; Thomas Rode; Scott L Hummel; Charles F Burant; Jonathan P Little; Jeffrey F Horowitz Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Paul T Reidy; Alec I McKenzie; Ziad Mahmassani; Vincent R Morrow; Nikol M Yonemura; Paul N Hopkins; Robin L Marcus; Matthew T Rondina; Yu Kuei Lin; Micah J Drummond Journal: J Physiol Date: 2018-10-09 Impact factor: 5.182
Authors: Mark W Pataky; Carmen S Yu; Yilin Nie; Edward B Arias; Manak Singh; Christopher L Mendias; Robert J Ploutz-Snyder; Gregory D Cartee Journal: Am J Physiol Endocrinol Metab Date: 2019-02-12 Impact factor: 4.310
Authors: Jacob T Seibert; Charles P Najt; Timothy D Heden; Douglas G Mashek; Lisa S Chow Journal: Trends Endocrinol Metab Date: 2020-09-08 Impact factor: 12.015
Authors: Esther Phielix; Paul Begovatz; Sofiya Gancheva; Alessandra Bierwagen; Esther Kornips; Gert Schaart; Matthijs K C Hesselink; Patrick Schrauwen; Michael Roden Journal: JCI Insight Date: 2019-11-01